A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
NCT ID: NCT00724334
Last Updated: 2025-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
42 participants
INTERVENTIONAL
2008-07-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
NCT01420770
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
NCT01437787
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
NCT01692366
Multiple Ascending Dose of BMS-911543
NCT01236352
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
NCT02784496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
SAR302503 (TG101348)
orally administered, once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SAR302503 (TG101348)
orally administered, once a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of myelofibrosis
* At least 18 years of age
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ayalew Tefferi, MD
Role: STUDY_CHAIR
Mayo Clinic, Rochester, MN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational Site Number 840103
La Jolla, California, United States
Investigational Site Number 840102
Stanford, California, United States
Investigational Site Number 840105
Boston, Massachusetts, United States
Investigational Site Number 840106
Ann Arbor, Michigan, United States
Investigational Site Number 840104
Rochester, Minnesota, United States
Investigational Site Number 840101
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MF-TG101348-002
Identifier Type: OTHER
Identifier Source: secondary_id
TED12015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.